ClinicalTrials.gg
RecruitingNCT05554393Updated Oct 28, 2026

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

A Phase 2 interventional study of Azacitidine and Biospecimen Collection in Acute Myeloid Leukemia, sponsored by National Cancer Institute (NCI). Recruiting at 187 sites in 3 countries. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 26, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Planned enrollment
41st of 211
153 · median 50
Started
2024
with 21 others
Phase 2
105 of 214
40 open now
Primary completion
2027-12
later than 46 of 90 live
Registered
138th of 214
by date
Lead sponsor
15 of 214
National Cancer Institute (NCI)

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 41st largest by planned enrollment of the 211 interventional ones that give a count, is one of 22 that started in 2024, is one of 105 in phase 2, reaches primary completion later than 46 of the 90 other live ones, and was the 138th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts with DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding venetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work better than the usual treatment of cytarabine with daunorubicin alone. To decide if they are better, the study doctors are looking to see if venetoclax increases the rate of elimination of AML in participants by 20% or more compared to the usual approach.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare the rates of undetectable measurable residual disease (MRD) in patients who achieve a complete remission (CR) after induction therapy with 7 +3 (cytarabine + daunorubicin hydrochloride [daunorubicin]) versus (vs.) azacitidine + venetoclax vs. 7+3 + venetoclax.

SECONDARY OBJECTIVES:

I. To estimate the frequency and severity of toxicities with each of the regimens.

II. To estimate complete remission (CR) rates (with and without MRD), complete remission with incomplete count recovery (CRi) (with and without MRD) rates, event-free survival (EFS), relapse-free survival (RFS), and overall survival (OS) with each of the regimens.

TERTIARY OBJECTIVES:

I. To evaluate response to therapy received according to genomic findings. II. To evaluate MRD kinetics by following patients with detectable MRD through Tier 2 and beyond.

III. To evaluate longer term outcomes by treatment arm, genomics, MRD outcome, and other features as patients receive additional myeloMATCH therapies to generate testable hypotheses for more precise patient selection for these therapies.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive daunorubicin intravenously (IV) on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax orally (PO) once daily (QD) on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening.

ARM II: Patients receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

ARM III: Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

After completion of study treatment, patients are followed up at 4 weeks, every 3 months for 1 year every 6 months for the second year and yearly thereafter.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have been registered to master screening and re-assessment protocol (MYELOMATCH) prior to consenting to this study. Participants must have been assigned to this clinical trial, via MATCHBox Protocol Assignment Team, prior to registration to this study. Participants must have agreed to have specimens submitted for translational medicine and must be offered the opportunity to submit biosamples for banking for future research as per MYELOMATCH

    • Note: Pre-enrollment/diagnosis labs must have already been performed under MYELOMATCH
  • Previously untreated, de novo acute myeloid leukemia (AML) defined by >= 20% myeloblasts in the peripheral blood or bone marrow (as defined by the current World Health Organization [WHO] classification of myeloid neoplasms and acute leukemia) excluding all the following categories of AML:

    • Favorable cytogenetics: (t(8;21)q22;q22.1); RUNX1-RUNX1T1, inversion 16(p13.1;q22), t(16;16)(p13.1;q22); CBFB-MYH11
    • CEBPA biallelic mutations
    • NPM1 mutation
    • AML with PML-RARalpha
    • AML with any adverse cytogenetics, TP53 mutation, RUNX1 mutation, ASXL1, 11q23/KMT2 rearrangements
    • AML with FLT3-ITD mutation
    • Therapy related AML, or AML following a diagnosis of myelodysplasia or myeloproliferative neoplasm Participants with central nervous system (CNS) disease are eligible for this trial and will be treated according to institutional guidelines with intrathecal chemotherapy for this aspect of their disease
  • Age 18-59 years at time of induction therapy
  • (ECOG) performance status =\< 3
  • Total =\< 2 x institutional (ULN) (must be done within 10 days of enrollment)
  • (AST) (serum glutamate pyruvate transaminase [SGPT]) and/or alanine aminotransferase (ALT) (serum glutamic-oxaloacetic transaminase [SGOT]) =\< 3 × institutional ULN (must be done within 10 days of enrollment)
  • Cardiac >= 50% (echocardiography or MUGA) (if clinically indicated must be done within 14 days of enrollment)
  • Calculated >= 30 mL/min; Clearance to be calculated using Cockcroft formula (must be done within 10 days of enrollment)
  • White blood cells (WBC) must be =\< 25 x 10\^9/L. Hydroxyurea and leukapheresis are permitted to control the WBC prior to enrollment and initiation of protocol-defined therapy but must be stopped prior to the initiation of protocol therapy. Hydroxyurea +/- no more than a total of 2500 mg cytarabine over a total of multiple days for urgent cytoreduction is also permitted
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class 2B or better
  • Males and females of must have agreed to use a highly effective method while on treatment and for 6 months after stopping study drug. A woman is considered to be of "" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.

Women of childbearing potential will have a pregnancy test to determine eligibility as part of the pre-study evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected. Patient will be considered eligible if an ultrasound is negative for pregnancy

  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
  • Patients must be accessible for treatment, response assessment and follow up. Patients enrolled on this trial must be treated and followed at the participating centre. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.

Patients must agree to return to their primary care facility for any adverse events which may occur through the course of the trial

  • In accordance with Canadian Cancer Trials Group (CCTG) policy, protocol treatment is to begin within 7 working days of patient enrollment
  • Patients with known (HIV) infection who are on effective anti-retroviral therapy and have undetectable viral load within 6 months of enrollment are eligible for this trial
  • Participants with evidence of chronic virus (HBV) infection must have undetectable HBV viral load within 28 days of enrollment. Patients need to be on suppressive therapy, if indicated
  • Patients with a history of virus (HCV) infection who have been treated and cured are eligible. Patients who with active HCV infection who are currently being treated must have an undetectable HCV viral load within 28 days of enrollment to be eligible

Exclusion criteria

Exclusion Criteria:

  • Prior therapy for AML except for hydroxyurea and leukapheresis to control blood counts. The use of all-trans retinoic acid (ATRA) is permitted until a diagnosis of acute promyelocytic leukemia, if suspected, is ruled out
  • Patients who are receiving any other agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to cytarabine, daunorubicin, azacitidine, venetoclax
  • Pregnant women are excluded from this study because venetoclax, cytarabine and azacitidine have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, cytarabine and azacitidine breastfeeding should be discontinued if the mother is treated with venetoclax, cytarabine and azacitidine. These potential risks may also apply to other agents used in this study
  • Patients with isolated myeloid sarcoma are not eligible
  • Any other serious intercurrent illness, life threatening condition, organ system dysfunction, or medical condition judged by the local investigator to compromise the subject's safety (for example):

    • Active, uncontrolled bacterial, fungal, or viral infection
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
153 participants (estimated)

Study arms

  • Experimental
    ARM I (daunorubicin, cytarabine, venetoclax)

    Patients receive daunorubicin IV on days 2-4, cytarabine IV continuously on days 2-8, and venetoclax PO QD on days 1-11. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of daunorubicin IV on days 2-3, cytarabine IV continuously on days 2-6, and venetoclax PO QD on days 1-8. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Drug: Cytarabine · Drug: Daunorubicin Hydrochloride · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Drug: Venetoclax

  • Experimental
    ARM II (azacitidine, venetoclax)

    Patients receive azacitidine IV or SC on days 1-7 or days 1-5 and 8-9 and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for a total of 2 cycles, in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

    Drug: Azacitidine · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Drug: Venetoclax

  • Active comparator
    ARM III (daunorubicin, cytarabine)

    Patients receive daunorubicin IV on days 1-3 and cytarabine IV, continuously, on days 1-7. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Based on a bone marrow aspiration assessment (completed at the discretion of the treating investigator), patients may receive reinduction consisting of cytarabine IV, continuously, on days 1-5 and daunorubicin IV on days 1-2. Cycle is 28 days and treatment is given in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspiration and collection of blood samples on study and as clinically indicated. Additionally, patients undergo ECHO or MUGA during screening.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Drug: Cytarabine · Drug: Daunorubicin Hydrochloride · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan

Interventions

  • Given IV or SC

    Also known as: 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • Given IV

    Also known as: .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453

  • Given IV

    Also known as: Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • Given PO

    Also known as: ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto

06

What researchers measure

Primary outcomes

  1. Measurable residual disease (MRD) undetectable complete remission (CR)

    Will assess after one induction cycle with or without the addition of venetoclax or two cycles of venetoclax and azacitidine. MRD by flow cytometry will be considered undetectable if ≤ 10\^-3. The MRD negative CR will be assessed using European LeukemiaNet (ELN) 2017 criteria \[Döhner 2017\]. The analysis population for the primary outcome will be all randomized patients with the intent to treat population. The MRD undetectable CR rate will be the number of patients with MRD undetectable CR divided by the total number of patients. The differences of MRD undetectable CR rates between the experimental groups and the control group will be estimated and the corresponding one-sided 90% confidence limit will be calculated using Normal distribution approximation. MRD non-evaluable patients will be considered as MRD positive.

    Time frame: Up to 2 cycles (56 days)

Secondary outcomes

  1. Frequency and severity of toxicities with each of the regimens

    All patients who have received at least one dose of study treatment will be included in the safety analysis. Adverse events will be graded using the Common Terminology Criteria for Adverse Events version 5.0. The incidence of adverse events will be summarized by type severity and relationship to the study drugs. A Fisher's exact test will be used to compare toxicities between the two arms, if needed.

    Time frame: Up to 10 years

  2. CR rates

    Will be assessed per 2017 ELN guidelines and will be tabulated. Exact 95% confidence intervals will be calculated.

    Time frame: Up to 2 cycles (56 days)

  3. Complete remission with incomplete count recovery (CRi)

    Will be assessed with and without MRD. Will be assessed per 2017 ELN guidelines and will be tabulated. Exact 95% confidence intervals will be calculated.

    Time frame: Up to 2 cycles (56 days)

  4. Event-free survival

    Patients not known to have any of these events are censored on the date of last contact. Will be described by the Kaplan-Meier estimate. The stratified log-rank test using the stratification factor at randomization will be used to test the difference between each experimental arms to the control arms.

    Time frame: From the date of randomization to the first: date of primary refractory disease; date of progressive disease; date off protocol therapy without CR or CRi; date of relapse from CR or CRi, or death from any cause, assessed up to 10 years

  5. Relapse-free survival

    Will be calculated for participants who have achieved a CR or CRi. For patients who have not relapsed or died, will be censored on the date of the last disease assessment. Will be described by the Kaplan-Meier estimate. The stratified log-rank test using the stratification factor at randomization will be used to test the difference between each experimental arms to the control arms.

    Time frame: From the time of CR or CRi, until the relapse from CR or CRi, or death from any cause, assessed up to 10 years

  6. Overall survival

    For patients who did not die, overall survival time will be censored at the time of last known alive date. Will be described by the Kaplan-Meier estimate. The stratified log-rank test using the stratification factor at randomization will be used to test the difference between each experimental arms to the control arms.

    Time frame: From enrollment to the time of death from any cause, assessed up to 10 years

  7. Responses to therapy received relative to genomic findings

    Will evaluate to gain insights toward more precise patient selection for optimal outcomes.

    Time frame: Up to 10 years

Other outcomes

  1. Comparative analysis by molecular characteristics

    Time frame: Up to 10 years

07

Study locations

177 of 187 sites recruiting

Showing the first 100 of 187 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2027, 39 months after the start.

Of 386 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 39 months is below that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2022
First posted
Sep 26, 2022
StartActual
Sep 13, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 3 sites changed recruiting status (2 now suspended, 1 now recruiting)
Show 3 sites
  • CancerCare Manitoba · Winnipeg, CanadaSuspended→Recruiting
  • OptumCare Cancer Care at Charleston · Las Vegas, United StatesRecruiting→Suspended
  • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesRecruiting→Suspended
Show site
  • Minnesota Oncology - Edina · Edina, United States
across 6 updates, Sep 28, 2026 – Oct 26, 2026
Site contacts
Changed at 9 sites. See the sites
Show 9 sites
  • CancerCare Manitoba · Winnipeg, CanadaContact added c•••@cancercare.mb.ca · •••1026Contact added (no phone or email listed)
  • OptumCare Cancer Care at Charleston · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
  • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
  • Providence Portland Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Saint Vincent Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • University of Alabama at Birmingham Cancer Center · Birmingham, United StatesContact added g•••@uabmc.eduContact added (no phone or email listed)
  • Nebraska Medicine-Bellevue · Bellevue, United StatesContact added u•••@unmc.edu · •••6941Contact added (no phone or email listed)
  • Nebraska Medicine-Village Pointe · Omaha, United StatesContact added •••5600Contact added (no phone or email listed)
  • University of Nebraska Medical Center · Omaha, United StatesContact added u•••@unmc.edu · •••6941Contact added (no phone or email listed)
across 5 updates, Sep 28, 2026 – Oct 16, 2026
Show all 6 updates
  1. Oct 26, 2026
    1 site added
    Show site
    • Minnesota Oncology - Edina · Edina, United States
  2. Oct 16, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Nebraska Medicine-Bellevue · Bellevue, United StatesSuspended→Recruiting
    • Nebraska Medicine-Village Pointe · Omaha, United StatesSuspended→Recruiting
    • University of Nebraska Medical Center · Omaha, United StatesSuspended→Recruiting
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Nebraska Medicine-Bellevue · Bellevue, United StatesContact added u•••@unmc.edu · •••6941Contact added (no phone or email listed)
    • Nebraska Medicine-Village Pointe · Omaha, United StatesContact added •••5600Contact added (no phone or email listed)
    • University of Nebraska Medical Center · Omaha, United StatesContact added u•••@unmc.edu · •••6941Contact added (no phone or email listed)
  3. Oct 15, 2026
    University of Alabama at Birmingham Cancer Center is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Alabama at Birmingham Cancer Center · Birmingham, United StatesContact added g•••@uabmc.eduContact added (no phone or email listed)
  4. Oct 14, 2026
    6 sites changed recruiting status (4 now suspended, 2 now recruiting)
    Show 6 sites
    • University of Alabama at Birmingham Cancer Center · Birmingham, United StatesRecruiting→Suspended
    • Nebraska Medicine-Bellevue · Bellevue, United StatesRecruiting→Suspended
    • Nebraska Medicine-Village Pointe · Omaha, United StatesRecruiting→Suspended
    • University of Nebraska Medical Center · Omaha, United StatesRecruiting→Suspended
    • Providence Portland Medical Center · Portland, United StatesSuspended→Recruiting
    • Providence Saint Vincent Medical Center · Portland, United StatesSuspended→Recruiting
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • University of Alabama at Birmingham Cancer Center · Birmingham, United StatesContact removed g•••@uabmc.eduContact removed (no phone or email listed)
    • Nebraska Medicine-Bellevue · Bellevue, United StatesContact removed u•••@unmc.edu · •••6941Contact removed (no phone or email listed)
    • Nebraska Medicine-Village Pointe · Omaha, United StatesContact removed •••5600Contact removed (no phone or email listed)
    • University of Nebraska Medical Center · Omaha, United StatesContact removed u•••@unmc.edu · •••6941Contact removed (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  5. Oct 6, 2026
    4 sites changed recruiting status (4 now suspended)
    Show 4 sites
    • OptumCare Cancer Care at Charleston · Las Vegas, United StatesRecruiting→Suspended
    • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesRecruiting→Suspended
    • Providence Portland Medical Center · Portland, United StatesRecruiting→Suspended
    • Providence Saint Vincent Medical Center · Portland, United StatesRecruiting→Suspended
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • OptumCare Cancer Care at Charleston · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
    • OptumCare Cancer Care at Fort Apache · Las Vegas, United StatesContact removed r•••@sncrf.org · •••0013Contact removed (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  6. Sep 28, 2026
    CancerCare Manitoba is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • CancerCare Manitoba · Winnipeg, CanadaContact added c•••@cancercare.mb.ca · •••1026Contact added (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05554393
Responsible party
Sponsor
First posted
Sep 26, 2022
Start date
Sep 13, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Mary L Savoie
principal investigator · Canadian Cancer Trials Group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Cytarabine · Daunorubicin · Venetoclax

Start the discussion